ArticleFrontiers in nutrition2026
A prediction tool for malnutrition and sarcopenia in patients with gastroenteropancreatic neuroendocrine neoplasms: results from NUTRIGETNE (GETNE-S2109) study.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Malnutrition and sarcopenia are prevalent among patients with gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs), necessitating simple assessment tools to identify potentially malnourished patients. After describing the nutritional status of those receiving anticancer treatment in Spain, the development of a nutrition screening tool for GEP-NENs was proposed as an exploratory objective of the NUTRIGETNE study. Methods: Malnutrition was defined by Global Leadership Initiative on Malnutrition (GLIM) criteria. Sarcopenia by European Working Group on Sarcopenia in Older People 2 (EWGSOP2) criteria. Patients were randomized 4:1 into training and validation sets to build a least absolute shrinkage and selection operator (LASSO) model. The model was corrected by sex, age, and body mass index. Predictors selected according to the area under the curve criterion were then used to fit the optimal model. Results: This study included 399 patients. Most had grade 1 or 2 (86.2%) tumors, originating mostly in the small intestine (43.9%) and pancreas (41.6%). Prevalence of malnutrition and sarcopenia was 61.9 and 15%, respectively. The predictive model had an external accuracy of 65.3 and 71.2% for malnutrition and sarcopenia, respectively. The stronger predictive factors for malnutrition were poor tumor differentiation (odds ratio [OR]: 4.4; 95% confidence interval [CI]: 1.2-22), nausea/vomiting (OR: 3.4; 95% CI: 1.4-9.3), having difficulties for a long walk (OR: 3; 95% CI: 1.8-5) and diabetes (OR: 2.2; 95% CI: 1.3-3.9). Sarcopenia was correlated with having troubles in activities of daily living (OR: 19.7; 95% CI: 3.1-390.9), or difficulties for a long walk (OR: 6.1; 95% CI: 2.6-15.5). Conclusion: A nomogram based on these models was developed. We generated a diagnostic tool for malnutrition and sarcopenia in patients with GEP-NENs to identify high-risk cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.